HBV’s morbidity arises in part from its ... Intracellular antigens, as well as the extracellular antigens found in the combination of virions and subviral particles, are believed to negatively ...

Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage ...

Combination-based tumor eradication in pre-clinical models produced innate and adaptive ... Indaptus’ Decoy product candidates have also produced significant single agent activity against chronic ...

Drug combination reaches key threshold for 'functional ... Hepatitis B is a lifelong infection of the liver caused by the hepatitis B virus (HBV) that can remain asymptomatic for decades.

including a phase 2b trial in combination with pegylated interferon and a phase 2 study alongside its HBV immunotherapy GSK3528869A. GSK licensed the drug from long-standing partner Ionis as part ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice ...

HBV affects almost 300 million people worldwide ... and is also exploring use of the drug in combination with current therapies including pegylated interferon (PegIFN) and its experimental ...

Biktarvy maintained HIV-1 suppression in 95.4% and HBV suppression in 86.6% of participants ... Results presented at CROI showed the treatment combination was generally well-tolerated with no ...